CTT Pharmaceutical Holdings Inc (CTTH)

[makinezmoney]

$CTTH: The Value of CCT-Pharma lies only in Water-Formulation PATENT


$CTTH doesn't need to make any money.

Aurora is well aware of that.

What Aurora wants is what $CTTH has.


Aurora wants it all for themselves and they realize the Great Potential
that the PATENT represents.


Dr. Pankaj Modi has US PATENT No. # 8,823,401 B2 for the Wafer FORMULATION
formerly known as FenWafe.


https://patents.google.com/patent/US9833461B2/en?inventor=Pankaj+Modi&sort=new






Pankaj Modi:


Since September 9, 2014 Dr. Modi has served as our Chief Executive Officer and Director. In
2007 Dr. Modi founded CTT Pharma. He was the original patent owner of our wafer and has been instrumental in
formulating various uses for the wafer. In 2006 he founded Transdermal Tech
Dr. Pankaj Modi, MD, PhD is a clinician and research scientist with experience in numerous medical areas. He is
founder and president of NeoMed Chemotherapeutics Corp, which is developing a cancer treatment option,
founder and president of Transdermal Corp, a dermatological specialty products company, co-founder and
president of SoftTouch Corp, which developed a minimally invasive micro-needle device for injectable drugs, and
founder and president of Photodyne Therapeutics Corp, which developed a novel dermatological therapy. Dr.
Modi was founder, director and VP, Research and Development, of Generex Biotechnology Corp, until 2005,
which developed a spray formula for use in the treatment of diabetes.
Previously, Dr. Modi gained 11 years of clinical experience conducting numerous large-scale clinical studies for
FDA approvals in areas including diabetes, thrombolysis, management of various skin diseases and aesthetic
cosmetic dermatology. He holds more than 25 US and Canadian patents and more than 280-plus world patents on
stabilized compositions, photosensitizer compounds, a topical anesthetic formulation, pharmaceutical
compositions, devices and methods and drug and vaccine delivery systems. Dr. Modi has obtained FDA approval
for 13 drugs successfully over the past five years and currently has seven applications in process. Among the
seven pending FDA approvals are five novel wound healing formulations and devices and two generic drugs to
treat diabetes.
Dr. Modi is an adjunct professor of Internal Medicine at OVC, University of Guelph, Canada; Instituto de
Endocrinologia Metabolismo y Reproduction, SA, Ecuador; Universidad de Buenos Aires (UBA); Sociedad
Argentina de Medicina Interna General, Cruz Roja Boliviana; Associaçao Médica Brasileira; Centro Universitario
de Ciencias de la Salud, Mexico; and Facultad de Salud Pública y Nutrición, Universidad Autónoma de Nuevo
León, Universidad Nacional de Asunción, UNA, Spain.
Dr. Pankaj Modi received his M.D. in internal medicine (diabetology) from the Instituto de Endocrinologia
Metabolismo y Reproduction, SA/University of Florida and completed a post-doctoral fellowship in neuroscience
at McMaster University in Hamilton, Canada. He earned a Ph.D. in chemistry, biochemistry and biomedical